Cancer glossary
MSI-H and dMMR on a pathology report: what they mean for you
What MSI-H, MSS and dMMR mean on your report: how they are tested by IHC and PCR, why they matter for immunotherapy and when Lynch syndrome testing is needed.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
MSI (microsatellite instability) and dMMR (mismatch repair deficiency) are two sides of the same problem: the tumor cannot fix errors made when DNA is copied. Such tumors build up many mutations and often respond well to immunotherapy.
How it appears in your report
Status is determined in two main ways:
- IHC for four proteins: ‘MLH1 retained, PMS2 retained, MSH2 loss of expression, MSH6 loss of expression. Conclusion: dMMR.’ If all four are stained, the result is pMMR (repair system intact).
- PCR: ‘High microsatellite instability (MSI-H) detected’ or ‘microsatellite stable tumor (MSS)’.
You may also see MSI-L, instability at a single locus. The status can also be reported as part of an NGS panel.
What it means
| Result | Meaning |
|---|---|
| dMMR | at least one of MLH1, MSH2, MSH6, PMS2 is lost |
| pMMR | all four proteins are retained |
| MSI-H | instability at two or more loci |
| MSS | no instability |
In most cases dMMR and MSI-H agree, but IHC and PCR occasionally disagree. When MLH1 is lost, labs usually also check MLH1 promoter methylation and the BRAF V600E mutation, which helps tell a sporadic change from Lynch syndrome.
Does it affect treatment
Yes. In 2017 the FDA approved a drug based on a biomarker rather than the organ for the first time: pembrolizumab for MSI-H/dMMR solid tumors at any site after prior treatment. In the studies behind that approval, 39.6% of 149 patients had an objective response. In colon cancer, MSI status is also weighed when deciding on chemotherapy after surgery. MSI-H/dMMR is also a reason to discuss Lynch syndrome testing, which matters for relatives. Treatment decisions rest with your treating doctor.
Questions to ask your doctor
- Has my MSI/MMR status been tested, and by which method?
- If I am dMMR, do I need a genetics consultation?
- Is immunotherapy an option in my situation?
More in the article on colorectal cancer treatment. If you are not sure the test was done, I can review your documents.
Sources
- FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication — U.S. FDA, 2017
- Tests for Colorectal Cancer — American Cancer Society, 2024
- Microsatellite instability: a review of what the oncologist should know — Cancer Cell International, 2020
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
